Its getting cheaper, sharks will grab again

YB @Khairykj hari ini menyaksikan majlis menandatangani dan pertukaran Memorandum Persefahaman tiga pihak (MoU) antara VentureTECH dengan DUOPHARMA Biotech Bhd dan Pangen biotech ke arah penubuhan kemudahan fasiliti biosimilar yang pertama di Malaysia.

Khairy said the development of the first biosimilar facility in the country would give Malaysians access to more affordable treatments especially for chronic diseases.

It said some of the potential impacts identified from the synergy included generating high-skilled employment, increasing the demand for highly-skilled local talents particularly in the high-value biopharmaceutical products and promoting technology adoption in making healthcare, especially chronic diseases that required biosimilar treatments more affordable to the public at large, especially the B40 and M40 group

Malaysia is set to have its first commercial biosimilar production facility in 2024 through a joint venture involving Government-backed impact investment company VentureTECH, Duopharma Biotech Bhd and South Korea-based biotechnology firm PanGen Biotech Inc.